New Analysis Report from Redeye

Redeye AB has revisited the Alzinova equity story following continued pipeline progress and the recent rights issue: "We continue to see the lead candidate, ALZ-101, as a candidate that stands out from other Alzheimer’s treatments. We argue that Alzinova offers an exciting investment opportunity and see an attractive entry point for the long-term oriented investor."